125 related articles for article (PubMed ID: 31889589)
1. Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells.
Ge XJ; Jiang JY; Wang M; Li MY; Zheng LM; Feng ZX; Liu L
Pathol Res Pract; 2020 Feb; 216(2):152798. PubMed ID: 31889589
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Mazard T; Causse A; Simony J; Leconet W; Vezzio-Vie N; Torro A; Jarlier M; Evrard A; Del Rio M; Assenat E; Martineau P; Ychou M; Robert B; Gongora C
Mol Cancer Ther; 2013 Oct; 12(10):2121-34. PubMed ID: 23960095
[TBL] [Abstract][Full Text] [Related]
4. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
Palshof JA; Cederbye CN; Høgdall EVS; Poulsen TS; Linnemann D; Nygaard SB; Stenvang J; Christensen IJ; Jensen BV; Pfeiffer P; Brünner N; Yilmaz M; Viuff BM; Nielsen DL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708825
[TBL] [Abstract][Full Text] [Related]
6. Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.
Ledys F; Derangère V; Réda M; Guion JF; Milliex R; Roux V; Limagne E; Arnould L; Bengrine L; Ghiringhelli F; Rébé C
Adv Ther; 2019 Jun; 36(6):1480-1484. PubMed ID: 30980281
[TBL] [Abstract][Full Text] [Related]
7. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway.
Nayak D; Tripathi N; Kathuria D; Siddharth S; Nayak A; Bharatam PV; Kundu C
Int J Biochem Cell Biol; 2020 Feb; 119():105682. PubMed ID: 31877386
[TBL] [Abstract][Full Text] [Related]
8. Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.
Santoro V; Jia R; Thompson H; Nijhuis A; Jeffery R; Kiakos K; Silver AR; Hartley JA; Hochhauser D
J Natl Cancer Inst; 2016 Jun; 108(6):djv394. PubMed ID: 26719345
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting the Activity of ABCG2 by KU55933 in Colorectal Cancer.
Liu K; Chen Y; Shi XB; Xing ZH; He ZJ; Wang ST; Li YC; Liu WJ; Zhang PW; Yu ZZ; Mo XM; Shi XY; Chen ZS; Shi Z
Recent Pat Anticancer Drug Discov; 2022; 17(4):387-395. PubMed ID: 35023460
[TBL] [Abstract][Full Text] [Related]
10. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
11. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Ata FK; Yalcin S
Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
[TBL] [Abstract][Full Text] [Related]
12. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
13. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
15. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
Lu Y; Shi C; Qiu S; Fan Z
Oncotarget; 2016 Oct; 7(40):64766-64777. PubMed ID: 27074568
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
